Neon Therapeutics
Personalized neoantigen-based cancer vaccines and T cell therapies
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Founded
- 2013
- Latest Form D
- $70M, Jan 2017
- Total capital
- $70M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $70M
- 1 Form D · last Jan 2017
- 118 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 1
- 39 pending · first 2023
- Rank in peer group#481 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$70M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#481 · top 33%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Cary Pfeffer, M.D.DirectorNamed in SEC Form D filings
- Daniella BeckmanExecutive OfficerNamed in SEC Form D filings
- Eric LanderDirectorNamed in SEC Form D filings
- Hugh DowdExecutive Officer, DirectorNamed in SEC Form D filings
- Richard Gaynor, M.D.Executive OfficerNamed in SEC Form D filings
- Robert Ang, M.D.Executive OfficerNamed in SEC Form D filings
Show all 10 people
- Robert KamenDirectorNamed in SEC Form D filings
- Robert TepperDirectorNamed in SEC Form D filings
- Stephen SherwinDirectorNamed in SEC Form D filings
- Yasir Al-WakeelExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 1 granted of 40- GrantedHla-based Methods And Compositions And Uses ThereofUSPTOUS 11,650,211
- PendingNeoantigens And Methods Of Their UseUSPTOApplication 16094851
- PendingMulti-domain Protein VaccineUSPTOApplication 62912903
Show all 40 patent records
- Hla-based Methods And Compositions And Uses ThereofMay 16, 2023 · US 11,650,211Granted
- Neoantigens And Methods Of Their UseOct 10, 2019 · Application 16094851Pending
- Multi-domain Protein VaccineApplication 62912903Pending
- Method And Systems For Prediction Of Class II Hla-specific Epitopes And Characterization Of CD4+T CellsApplication 62855379Pending
- Compositions And Methods For Preparing T Cell Compositions And Uses ThereofApplication 62827018Pending
- Method And Systems For Prediction Of Class II Hla-specific Epitopes And Characterization Of CD4+T CellsApplication 62826827Pending
- Cancer Microenvironment Biomarkers For Durable Clinical BenefitApplication 62826813Pending
- T Cell Receptor Constructs And Uses ThereofApplication 62810112Pending
- Neoantigens And Uses ThereofApplication 62801981Pending
- Neoantigens And Uses ThereofApplication 62800700Pending
- Neoantigens And Uses ThereofApplication 62800792Pending
- Neoantigens And Uses ThereofApplication 62800735Pending
- Neoantigens And Uses ThereofApplication 62789162Pending
- Method And Systems For Identification And Prediction Of Class II Hla-specific EpitopesApplication 62783914Pending
- Neoantigens And Uses ThereofApplication 62726804Pending
- T cell receptor constructs and uses thereofApplication 62764817Pending
- Neoantigens And Uses ThereofApplication 62702567Pending
- Neoantigens And Uses ThereofApplication 62687188Pending
- Neoantigens And Uses ThereofApplication 62687191Pending
- Combination Therapy With Neoantigen VaccineApplication 62684013Pending
- Immunogenic Neoantigen IdentificationApplication PCTUS2018033539Pending
- Peptide Formulations And Uses ThereofApplication 62660027Pending
- Protein Antigens And Uses ThereofApplication PCTUS2018025933Pending
- Hla-based Methods And Compositions And Uses ThereofApplication PCTUS2018017849Pending
- Neoantigens And Uses ThereofApplication 62607148Pending
- Immunogenic Neoantigen IdentificationApplication 62508754Pending
- Neoantigens And Methods Of Their UseApplication 62480593Pending
- Neoantigens And Methods Of Their UseApplication 62480596Pending
- Neoantigens And Methods Of Their UseApplication 62480597Pending
- Neoantigens And Methods Of Their UseApplication PCTUS2017025462Pending
- Hla-based Methods And Compositions And Uses ThereofApplication 62461162Pending
- Neoantigen Methods And Compositions And Uses ThereofApplication 62457978Pending
- Neoantigens And Methods Of Their UseApplication 62316567Pending
- Neoantigens And Methods Of Their UseApplication 62316571Pending
- Neoantigens And Methods Of Their UseApplication 62316547Pending
- Neoantigens And Methods Of Their UseApplication 62316533Pending
- Neoantigens And Methods Of Their UseApplication 62316530Pending
- Cancer Biomarkers For Durable Clinical BenefitApplication 62986418Pending
- Neoantigens And Methods Of Their UseApplication 62316552Pending
- Cancer Biomarkers For Durable Clinical BenefitApplication 62914767Pending
Related companies, and why
- Vera Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Epicrispr Biotechnologies, Inc.Similar federal contract value in Biotech · null in contracts
- Elevation OncologySimilar federal contract value in Biotech · null in contracts
- Dimension TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Progentos TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Arcturus BiotherapeuticsSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .